CPRX
Catalyst Pharmaceuticals Inc
Halal Rating :
Last Price
$22.82
Last updated:
Market Cap
-
7D Change
2.75%
1 Year Change
50.63%
Company Overview
Industries
Exchange
Next Earnings Date
Catalyst Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. Their flagship product is FIRDAPSE® (amifampridine), an FDA-approved treatment for Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $128.69m | $77.79m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $122.71m | $68.46m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $98.51m | $71.38m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Catalyst Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.